🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
0.8532
+0.0166 (1.98%)
At close: Nov 18, 2026, 4:00 PM EST
0.8532
0.00 (0.00%)
After-hours: Nov 18, 2026, 4:00 PM EST

Marker Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2.313.556.593.313.511.24
Revenue Growth
-33.60%-46.19%99.06%-5.76%182.96%166.01%
Cost of Revenue
2.1411.813.4710.4211.9727.79
Gross Profit
0.17-8.25-6.88-7.11-8.45-26.55
Selling, General & Admin
4.284.184.247.4811.3412.92
Research & Development
6.49-----
Operating Expenses
10.774.184.247.4811.3412.92
Operating Income
-10.6-12.44-11.12-14.58-19.79-39.48
Interest & Investment Income
0.50.590.440.540.250.01
Other Non Operating Income (Expenses)
1.520.12----
EBT Excluding Unusual Items
-8.57-11.73-10.68-14.04-19.54-39.47
Other Unusual Items
--0.45---0.23-2.41
Pretax Income
-8.57-12.18-10.68-14.04-19.78-41.88
Income Tax Expense
-0.02-0.020.050--
Earnings From Continuing Operations
-8.55-12.16-10.73-14.05-19.78-41.88
Earnings From Discontinued Operations
---5.81-10.15-
Net Income
-8.55-12.16-10.73-8.24-29.93-41.88
Net Income to Common
-8.55-12.16-10.73-8.24-29.93-41.88
Net Income Growth
------
Shares Outstanding (Basic)
19159988
Shares Outstanding (Diluted)
19159988
Shares Change
51.63%70.49%1.94%5.49%9.16%62.64%
EPS (Basic)
-0.44-0.79-1.19-0.94-3.58-5.47
EPS (Diluted)
-0.44-0.79-1.19-0.94-3.59-5.47
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-9.52-12.01-10.91-16.44-26.97-30.41
Free Cash Flow Per Share
-0.49-0.79-1.22-1.87-3.23-3.98
Gross Margin
7.47%-232.68%-104.33%-214.60%-240.64%-
Operating Margin
-457.96%-350.67%-168.69%-440.37%-563.28%-3179.32%
Profit Margin
-369.67%-342.96%-162.82%-248.76%-851.87%-3372.68%
Free Cash Flow Margin
-411.25%-338.74%-165.53%-496.51%-767.66%-2449.11%
EBITDA
----11.79-17-37.33
D&A For EBITDA
---2.792.792.15
EBIT
-10.6-12.44-11.12-14.58-19.79-39.48
EBIT Margin
---168.69%---
Revenue as Reported
2.313.556.593.313.511.24
SEC Filings: 10-K · 10-Q